European Medicines Agency Approves Once Every Two Weeks Dosing Option For CSL Behring UK Ltd’s Hizentra® (Human Normal Immunoglobulin, SCIg)

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAYWARDS HEATH, England--(BUSINESS WIRE)--CSL Behring UK Ltd announced today that the European Medicines Agency (EMA) has expanded the administration options for Hizentra®?, human normal immunoglobulin, SCIg, 20% liquid, to include dosing once every two weeks (fortnightly).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC